Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 2

Status

Unknown 9Recruiting 7Not yet recruiting 5Active not recruiting 4Withdrawn 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Carcinoma, Non-Small-Cell Lung 133Breast Neoplasms 95Colorectal Neoplasms 65Carcinoma, Hepatocellular 57Squamous Cell Carcinoma of Head and Neck 48Stomach Neoplasms 46Lung Neoplasms 44Triple Negative Breast Neoplasms 43Prostatic Neoplasms 43Leukemia, Myeloid, Acute 43Small Cell Lung Carcinoma 41Uterine Cervical Neoplasms 40Rectal Neoplasms 37Neoplasms 31Pancreatic Neoplasms 30Recurrence 29Neoplasm Metastasis 29Esophageal Squamous Cell Carcinoma 25Esophageal Neoplasms 24Ovarian Neoplasms 23Nasopharyngeal Carcinoma 21Carcinoma, Renal Cell 21Brain Neoplasms 21Melanoma 20Lymphoma, Large B-Cell, Diffuse 20Colonic Neoplasms 20Endometrial Neoplasms 19Multiple Myeloma 18Head and Neck Neoplasms 18Biliary Tract Neoplasms 18

Interventions

pyrotinib 3Trastuzumab 3pertuzumab 1exemestane 1dalpiciclib 1Leuprolide 1Goserelin 1Fulvestrant 1Docetaxel 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × HER2-positive Breast Cancer × Clear all
NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
80 enrolled
Breast

HER2-positive Breast Cancer

NCT06973525 2025-08-05

HER2-DM-NACT

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
30 enrolled
Breast

HER2-positive Breast Cancer

NCT06548178 2024-08-12

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Fudan University

Phase 2 Not yet recruiting
242 enrolled
Breast

HER2-positive Breast Cancer

NCT04158856 2019-11-12

SHERO

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
60 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡